Actively Recruiting
Combined Anabolic Therapy
Led by Massachusetts General Hospital · Updated on 2026-04-17
50
Participants Needed
1
Research Sites
164 weeks
Total Duration
On this page
Sponsors
M
Massachusetts General Hospital
Lead Sponsor
N
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborating Sponsor
AI-Summary
What this Trial Is About
In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.
CONDITIONS
Official Title
Combined Anabolic Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 45 years and older
- Postmenopausal
- Diagnosed with osteoporosis and at high risk of fracture
You will not qualify if you...
- Significant previous use of bone health modifying treatments
- Known congenital or acquired bone disease other than osteoporosis
- Significant renal, liver, cardiopulmonary, or psychiatric disease
- Abnormal calcium or parathyroid hormone levels
- Serum vitamin D level below 20 ng/dL
- Anemia with hematocrit below 32%
- History of malignancy except non-melanoma skin carcinoma
- Excessive alcohol use or substance abuse
- Known contraindications to romosozumab or teriparatide
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
Research Team
A
Aparna Patnaik, BA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here